PT-141 / bremelanotide
PT-141, desire ratings and the brain
PT-141 and bremelanotide name the same active substance. The women in the trials, the scans and the animal experiments each supply a different kind of answer.
Desire and distress in RECONNECT
In two randomized phase 3 trials called RECONNECT, 1,267 premenopausal women with hypoactive sexual desire disorder were enrolled. Over 24 weeks, bremelanotide improved desire ratings and reduced distress about low desire more than placebo.
These women had acquired, generalized HSDD: distressing low desire that developed after previously having more desire and persisted across partners and situations. That description gives the outcome its setting. The approved indication concerns premenopausal women with this condition; it excludes men, postmenopausal women and general sexual-performance enhancement.
I put the women's ratings ahead of the more visually impressive scan results. A treatment for distressing low desire has to earn its value in the experiences it aims to change. Trial questionnaires address that question directly, even though an average improvement leaves room for very different individual experiences.
The brain-imaging experiment
A crossover study in 31 premenopausal women with HSDD found increased sexual desire for up to 24 hours and altered brain responses to erotic images. Activity in the amygdala and insula, regions involved in emotion and awareness of the body, became more closely linked.
Bremelanotide activates central melanocortin receptors, particularly MC4R. The experiment helps explain how a brain pathway can influence desire. It also leaves an important gap between an image of brain activity and the experience of the person being scanned.
To me, the scan is most useful when it sits beside the reported desire change. Taken alone, a bright patch in a brain image can acquire a persuasive power far beyond the question the experiment answered.
Hamster findings
The female Syrian hamster experiment complicates an easy reward story. Bremelanotide did not enhance conditioned place preference for sexual interaction, the test the researchers used to examine sexual reward. It also did not change melanocortin-receptor mRNA expression in the mesolimbic dopamine system.
The mRNA measurement concerns instructions for producing receptors. The place-preference test concerns an animal's behaviour. Neither can stand in for the women's reports in RECONNECT, and the negative result cannot erase those reports.
I appreciate a finding that leaves the proposed explanation untidy. Desire and reward can be pulled apart experimentally; a medicine's reputation tends to bundle them together. This hamster result makes that bundle less convincing without settling what any particular woman will experience.
Follow-up, blood pressure and skin changes
The 52-week open-label extension enrolled 684 women. Improvements were sustained and no new safety signals emerged, while nausea, flushing and headache remained the common adverse effects. Everyone knew the treatment in this extension, which changes how its results can be interpreted alongside a placebo-controlled trial.
The prescribing information warns of a temporary blood-pressure rise. Uncontrolled hypertension or known cardiovascular disease is a contraindication. High blood pressure that remains elevated despite treatment is uncontrolled; pressure controlled with medication does not meet that particular contraindication. Some areas of skin or gums may remain darker after treatment ends.
Community accounts describe increased desire, arousal or pleasure, as well as nausea, tingling, drowsiness and experiences of no benefit. These are anecdotal accounts, not clinical evidence. They cannot establish an effect rate or extend the approved indication. Material described as a PT-141 research chemical also lacks the approved medicine's assurance of identity, concentration and cleanliness.